-- FACTBOX: Pfizer-Wyeth deal
-- 
-- Mon Jan 26, 2009 12:27pm EST
-- http://www.reuters.com/article/2009/01/26/us-wyeth-pfizer1sb-idUSTRE50P56I20090126

 

 (Reuters) - Pfizer Inc, the world's biggest drugmaker, said it would buy rival Wyeth for $68 billion in a deal expected to dramatically reshape the cash-rich pharmaceutical industry by setting off a string of takeovers and mergers. 

 Below are some facts about the deal, which on completion would be the third-largest ever in the pharmaceutical industry: TERMS * Price - Pfizer to pay $50.19 per share -- $33 in cash and 0.985 share of its stock -- for each Wyeth share. Represents a 29 percent premium to the price of Wyeth shares before news of the deal leaked last week. The offer is a 20 percent premium to the average price target of 11 analysts for Wyeth pre-deal of $41.68, with a range of $33-$46, according to Jefferies & Co. * Financing - The deal would be financed through a combination of cash, debt and stock. A consortium of banks provided commitments for a total of $22.5 billion in debt. * Impact - The deal is expected to add to Pfizer's earnings in the second full year after closing and result in cost savings of $4 billion by the third year. COMBINED COMPANY * CEO -- Jeff Kindler * Employees -- 129,500. Pfizer said it plans to cut about 15 percent of the combined workforce. * Revenue -- $71.3 billion * Market share - The combined company would have about 12 percent market share in the United States, about 10 percent in Europe, and about 6 percent in Japan. * Medicines to treat such areas as cardiovascular, oncology, women's health, central nervous system and infectious disease, and a product portfolio including 17 products with more than $1 billion each in annual revenue. (Reporting by  Esha Dey  in Bangalore)